×
About 11,645 results

ALLMedicine™ Mesothelioma Center

Research & Reviews  3,779 results

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From ...
https://clinicaltrials.gov/ct2/show/NCT05375825

Jan 27th, 2023 - Background Malignant pleural mesotheliomas (MPM) are aggressive cancers with a high predilection for intrapleural recurrences despite potentially curative resections. Pleural metastases and associated malignant pleural effusions (MPE) cause consid...

Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas ...
https://clinicaltrials.gov/ct2/show/NCT04431024

Jan 26th, 2023 - Background: Mutations involving BRCA1-Associated Protein-1 (BAP1), a nuclear deubiquitinase involved in epigenetic regulation of gene expression, DNA repair, and cellular energetics, have emerged as one of the most common somatic mutations in mali...

Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT03399552

Jan 26th, 2023 - The purpose of this study is to find out whether the combination of avelumab and SBRT is safe and what effect avelumab has on mesothelioma when given in combination with SBRT. In addition, a goal of this protocol is to study the effect of radiatio...

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT04840615

Jan 25th, 2023 - Background: LMB-100, and a closely related immunotoxin, SS1P, also targeting mesothelin, given intravenously, have been studied in Phase 1 clinical studies for mesothelioma and pancreatic cancer. LMB-100 given intravenously, results in systemic in...

Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
https://clinicaltrials.gov/ct2/show/NCT03683680

Jan 25th, 2023 - The purpose of this research study is to test a new method for determining the stage and prognosis of patients with malignant pleural mesothelioma. Currently, it is not possible to accurately determine cancer stage prior to surgery or another trea...

see more →

Guidelines  14 results

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatm...
https://doi.org/10.1016/j.annonc.2021.11.005
Annals of Oncology : Official Journal of the European Soc... Popat S, Baas P et. al.

Dec 4th, 2021 - Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.|2021|Popat S,Baas P,Faivre-Finn C,Girard N,Nicholson AG,|

SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057959
Clinical & Translational Oncology : Official Publication ... Nadal E, Bosch-Barrera J et. al.

Feb 5th, 2021 - Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in ...

Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, trea...
https://doi.org/10.1016/j.ejso.2020.02.011
European Journal of Surgical Oncology : the Journal of Th... Kusamura S, Kepenekian V et. al.

Mar 27th, 2020 - Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up.|2020|Kusamura S,Kepenekian V,Villeneuve L,Lurvink RJ,Govaerts K,|diagnosis,pathology,therapy,diagnosis,pathology,therapy,

ERS/EACTS statement on the management of malignant pleural effusions.
https://doi.org/10.1183/13993003.00349-2018
The European Respiratory Journal; Bibby AC, Dorn P et. al.

Jul 29th, 2018 - Malignant pleural effusions (MPE) are a common pathology, treated by respiratory physicians and thoracic surgeons alike. In recent years, several well-designed randomised clinical trials have been published that have changed the landscape of MPE m...

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clin...
https://doi.org/10.1200/JOP.17.00012
Journal of Oncology Practice; Kindler HL, Ismaila N et. al.

Mar 9th, 2018 - Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline Summary.|2018|Kindler HL,Ismaila N,Hassan R,|diagnosis,therapy,diagnosis,therapy,diagnosis,therapy,

see more →

Drugs  32 results see all →

Clinicaltrials.gov  415 results

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From ...
https://clinicaltrials.gov/ct2/show/NCT05375825

Jan 27th, 2023 - Background Malignant pleural mesotheliomas (MPM) are aggressive cancers with a high predilection for intrapleural recurrences despite potentially curative resections. Pleural metastases and associated malignant pleural effusions (MPE) cause consid...

Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas ...
https://clinicaltrials.gov/ct2/show/NCT04431024

Jan 26th, 2023 - Background: Mutations involving BRCA1-Associated Protein-1 (BAP1), a nuclear deubiquitinase involved in epigenetic regulation of gene expression, DNA repair, and cellular energetics, have emerged as one of the most common somatic mutations in mali...

Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT03399552

Jan 26th, 2023 - The purpose of this study is to find out whether the combination of avelumab and SBRT is safe and what effect avelumab has on mesothelioma when given in combination with SBRT. In addition, a goal of this protocol is to study the effect of radiatio...

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT04840615

Jan 25th, 2023 - Background: LMB-100, and a closely related immunotoxin, SS1P, also targeting mesothelin, given intravenously, have been studied in Phase 1 clinical studies for mesothelioma and pancreatic cancer. LMB-100 given intravenously, results in systemic in...

Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
https://clinicaltrials.gov/ct2/show/NCT03683680

Jan 25th, 2023 - The purpose of this research study is to test a new method for determining the stage and prognosis of patients with malignant pleural mesothelioma. Currently, it is not possible to accurately determine cancer stage prior to surgery or another trea...

see more →

News  403 results

Study Supports Routine Omentectomy in Absence of Metastasis During CRS-HIPEC
https://www.medpagetoday.com/hematologyoncology/othercancers/102596

Jan 11th, 2023 - Almost one-third of patients undergoing omentectomy for peritoneal metastases had occult omental metastases, supporting routine omentectomy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), authors of a retr...

FDA Grants Orphan Drug Designation to SynKIR-110 for Mesothelin-Expressing Mesothelioma
https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-synkir-110-for-mesothelin-expressing-mesothelioma

Oct 27th, 2022 - The FDA has granted an orphan drug designation (ODD) to SynKIR-110, a first-in-class KIR-CAR T-cell immunotherapy candidate, for the treatment of patients with mesothelin-expressing mesothelioma.1 SynKIR-110 is a next-generation cell therapy desi...

177Lu-FAP-2286 Displays Preliminary Antitumor Activity in Advanced or Metastatic Solid Tumors
https://www.onclive.com/view/177lu-fap-2286-displays-preliminary-antitumor-activity-in-advanced-or-metastatic-solid-tumors

Oct 18th, 2022 - The targeted radiotherapy candidate lutetium-177-FAP-2286 (177Lu-FAP-2286) produced preliminary evidence of antitumor activity with a manageable safety profile in patients with advanced or metastatic solid tumors, according to data from the phase ...

Is Therapeutic Value a New Name for Medical Paternalism?
https://www.onclive.com/view/is-therapeutic-value-a-new-name-for-medical-paternalism-

Oct 14th, 2022 - A landmark essay by the late eminent evolutionary biologist Stephen J. Gould, PhD, entitled The Median Isn’t the Message serves as an excellent opening for this commentary. Gould, after receiving a diagnosis of primary peritoneal mesothelioma, wha...

US Judge Temporarily Blocks Two State Lawsuits Over J&J Talc Marketing
https://www.medscape.com/viewarticle/981895

Oct 6th, 2022 - (Reuters) - A U.S. bankruptcy judge has blocked New Mexico and Mississippi from pursuing lawsuits accusing Johnson & Johnson of misleading consumers about the safety of its talc products, such as its baby powder, for now. U.S. Bankruptcy Judge Mic...

see more →

Patient Education  15 results see all →